Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Awad

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
Biorxiv : the Preprint Server for Biology|February 23, 2026
Evolution of oncogene amplification across 86,000 cancer cell genomesJake June-Koo Lee, Sohrab Salehi, Matthew A Myers, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation StatusBiagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Cancer Immunology Research|April 24, 2020
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid TumorsSarah Abou Alaiwi, Amin H Nassar, Wanling Xie, et al.
Nature Medicine|December 16, 2022
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Sarah Abou Alaiwi, Wenxin Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
Biorxiv : the Preprint Server for Biology|February 23, 2026
Evolution of oncogene amplification across 86,000 cancer cell genomesJake June-Koo Lee, Sohrab Salehi, Matthew A Myers, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation StatusBiagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Cancer Immunology Research|April 24, 2020
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid TumorsSarah Abou Alaiwi, Amin H Nassar, Wanling Xie, et al.
Nature Medicine|December 16, 2022
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Sarah Abou Alaiwi, Wenxin Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.
Pageof 21